Skip to main content

2 Result(s)

within Edmond G. Fita Remove this filter

and

  1. Article

    Open Access

    Efficacy and Safety of IDegAsp Versus BIAsp 30, Both Twice Daily, in Elderly Patients with Type 2 Diabetes: Post Hoc Analysis of Two Phase 3 Randomized Controlled BOOST Trials

    The majority of elderly patients (≥ 65 years of age) with type 2 diabetes mellitus (T2DM) will eventually require insulin therapy, but they are particularly vulnerable to hypoglycemia and challenging to treat....

    Greg Fulcher, Roopa Mehta, Edmond G. Fita, Magnus Ekelund… in Diabetes Therapy (2019)

    Download PDF (822 KB) View Article

  2. Article

    Open Access

    A Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use

    Insulin degludec/insulin aspart (IDegAsp; 70 % IDeg and 30 % IAsp) is a soluble combination of two individual insulin analogues in one product, designed to provide mealtime glycaemic control due to the IAsp co...

    Hanne Haahr, Edmond G. Fita, Tim Heise in Clinical Pharmacokinetics (2017)

    Download PDF (1158 KB) View Article